Your Lp(a) at 74.9 nmol/L: Aggressive Risk Factor Management is Essential
With your Lp(a) at 74.9 nmol/L—just below the 75 nmol/L threshold—you should treat this as a risk-enhancing factor and aggressively manage all other cardiovascular risk factors, particularly LDL cholesterol. While you're technically below the commonly cited cutoff, the evidence shows cardiovascular risk increases in a dose-dependent fashion starting above 30 mg/dL (approximately 60-75 nmol/L), and your level places you at the cusp of significantly elevated risk 1.
Why This Matters
Your Lp(a) level is genetically determined and won't change with diet, exercise, or most medications 1. The 2021 Canadian Cardiovascular Society guidelines—the most recent and comprehensive guidance—recommend measuring Lp(a) once in a lifetime and using ≥50 mg/dL (≥100 nmol/L) as the threshold for intensive intervention 1. However, epidemiological data from the Copenhagen Heart Study shows that even levels between 30-76 mg/dL (roughly 60-150 nmol/L) carry a 1.7-fold increased risk of myocardial infarction 1.
The critical point: You're in a gray zone where risk is elevated but not dramatically so—this is precisely where aggressive management of modifiable risk factors becomes crucial.
What You Should Do Now
1. Calculate Your 10-Year ASCVD Risk
Determine your overall cardiovascular risk using the Pooled Cohort Equations or similar validated risk calculator 2. Your Lp(a) level should be considered a risk-enhancing factor that may move you into a higher risk category 2, 3.
2. Aggressive LDL Cholesterol Management
If you have established cardiovascular disease or diabetes:
- Target LDL-C <1.8 mmol/L (70 mg/dL) or at least 50% reduction from baseline 4
- High-intensity statin therapy is the foundation 4, 1
- Consider adding ezetimibe and/or PCSK9 inhibitors if LDL-C goal not met 1
If you're in primary prevention (no prior cardiovascular events):
- With borderline-to-intermediate risk (5-19.9% 10-year risk): Consider moderate-to-high intensity statin therapy, especially if other risk-enhancing factors are present 2, 3
- With high risk (≥20% 10-year risk): High-intensity statin therapy is recommended 2
3. Consider Coronary Artery Calcium (CAC) Scoring
If your treatment decision remains uncertain—particularly if you're at borderline or intermediate risk—CAC scoring can help guide whether to initiate or intensify therapy 2, 3. This is especially valuable at your Lp(a) level where you're on the threshold:
- CAC = 0: May defer statin therapy with close monitoring
- CAC >0: Strongly favors statin initiation
- CAC ≥100 or >75th percentile for age/sex/race: Definitely initiate statin therapy 3
4. Optimize All Modifiable Risk Factors
The 2021 Canadian guidelines explicitly recommend "earlier and more intensive health behaviour modification counselling and management of other ASCVD risk factors" for patients with elevated Lp(a) 1. This means:
- Blood pressure control: Target <130/80 mmHg
- Smoking cessation: Absolute priority
- Weight management: Achieve healthy BMI
- Physical activity: Regular aerobic exercise
- Diabetes management: If present, optimize glycemic control
- Anti-inflammatory diet: Mediterranean-style eating pattern
5. Family Screening
Since Lp(a) is >90% genetically determined, consider cascade testing of first-degree relatives, particularly if you have a family history of premature cardiovascular disease 1, 5. This is especially important if anyone in your family has had cardiovascular events before age 55 (men) or 60 (women).
Important Caveats
Current therapies don't effectively lower Lp(a):
- Statins and ezetimibe have minimal effect on Lp(a) 1
- PCSK9 inhibitors lower Lp(a) by only 20-30%, which is modest 1
- Niacin lowers Lp(a) but is no longer recommended due to lack of cardiovascular benefit 6
You don't need repeat Lp(a) testing since levels remain stable throughout life 1.
Novel therapies are coming: Antisense oligonucleotides and small interfering RNAs that can reduce Lp(a) by 80-95% are in clinical trials 1, but these are not yet available for routine use.
The Bottom Line
At 74.9 nmol/L, you're at the threshold where Lp(a) begins to meaningfully increase cardiovascular risk. The most important action is to ensure your LDL cholesterol is optimally controlled and all other modifiable risk factors are aggressively managed. This is not a "wait and see" situation—your Lp(a) won't change, so the time to act on other risk factors is now. Consider CAC scoring if you're uncertain about starting statin therapy, and discuss with your physician whether your overall risk profile warrants more intensive lipid-lowering treatment 1, 2, 3.